This study investigates retrospectively, in selected patients, the ischemic outcome (reversible ischemia, infarction, and hemorrhage) and neurologic outcome of acute stroke treated with intra-arterial thrombolysis and the predictive value of pretreatment single-photon emission-computed tomography (SPECT). Thirty patients with complete recanalization within 12 hours were analyzed. The extent of ischemia was outlined on SPECT, and two CBF parameters were calculated: the ratio of ischemic regional activity to CBF in the cerebellum and the asymmetry index. Reversible ischemia, infarction, and hemor rhage were identified by comparing SPECT and follow-up computed tomography. Nine patients (30%) had no or small infarction, 14 (47%) had medium or large infarction, and seven (23%) had hemorrhage. Forty-two lesions were identified (22 reversible ischemia, 13 infarction, and 7 hemorrhage). Duration of ischemia, urokinase dose, disease type, and occlusion site
and complication rate vary among different institutions. Many factors that may influence the ischemic outcome (reversible ischemia, infarction, and hemorrhage) and neurologic outcome (National Institutes of Health [NIH] stroke scores and clinical findings) have been proposed. These include patient characteristics, nature and duration of ischemia, technical variation, and clinical relevance. No firm data prove or disprove the existence of other factors or the degree of their influence on outcomes. There is no established protocol in dealing with intra arterial thrombolytic therapy, particularly the guidelines for proper patient selection.
Single-photon emission-computed tomography (SPECT) as a noninvasive brain perfusion imaging mo dality is expected to have potential value in the assess ment of tissue reversibility before treatment (Giubilei et aI., 1990; Hanson et aI., 1993; Baired et aI., 1994) . Al though Alexandrov and colleagues (1997 b) suggest the need for the clinical value of SPECT applicable to pa tient selection for thrombolysis, pretreatment assessment of parameters reflecting the perfusion status of the isch-emic tissue has not been part of treatment protocol in the past. Our previous report indicates that the risk of hem orrhagic transformation in acute stroke patients treated by intra-arterial thrombolytic therapy depended on re sidual CBF of ischemic tissue judged by pretreatment SPECT (Ueda et aI., 1994) . Finally, complete recanali zation was not achieved in all of the patients studied in prior reports, which suggests that technical factors may influence outcomes. This study investigates the ischemic and neurologic outcomes of acute stroke patients with early and complete recanalization using intra-arterial thrombolytic therapy and assesses the value of pretreat ment SPECT in the prediction of outcomes. Specifically, we tested the hypothesis that the parameters provided by pretreatment SPECT can be helpful in patient selection and improving outcomes.
MATERIALS AND METHODS
Eighty-five selected patients treated in our institution be tween April 1989 and March 1996 using intra-arterial throm bolytic therapy for acute ischemic stroke were evaluated retro spectively. Of the 85 patients, 45 were studied with SPECT using technetium-99m-labeled hexamethylpropyleneamine ox ime e9mTc-HMPAO) before the treatment. Thirty of these 45 patients who also had complete recanalization less than 12 hours after the onset of symptoms were included in the current study. These patients included 16 men and 14 women between 35 and 83 years of age (mean ± SD, 67 ± 10 years). The duration of ischemia is the time after onset rounded to the nearest hour.
The inclusion criteria for this study were as follows: (1) no apparent hypodense areas were observed on the admission computed tomographic (CT) scan; (2) it was preferred that the patient was treated within 6 hours (87%) but no later than 12 hours; (3) occluded arteries suggested by symptoms were dem onstrated by cerebral angiography; and (4) informed consent was obtained from the patient or relatives. The exclusion cri teria were as follows: (1) recent hemorrhagic stroke; (2) critical systemic condition; (3) serious disabling disease; (4) classic contraindications to thrombolytic therapy (recent surgical op eration, gastrointestinal bleeding, or known bleeding ten dency).
The CT was performed on admission, immediately after therapy, the following day, and 1 week, 2 weeks, and 1 month after therapy. When no clear hypodense areas were observed at the sites suggested by clinical symptoms, HMPAO-SPECT was performed using a rotational gamma camera (GCA602A, Toshiba, Tokyo, Japan) or a four-head gamma camera (SPECT2000H-40, Hitachi, Tokyo, Japan) with a low-energy high-resolution collimator. The patients were injected with 30 mCi of 99mTc_HMPAO. About 5 minutes later, emission pro jection data were acquired in 60 views over 3600 for 12 seconds per view using a 64 x 64 matrix in the former camera and in 64 views over 3600 for 20 seconds per view using a 64 x 64 matrix in the latter one. The pixel size was 4.0 x 4.0 mm. The slice thicknesses were 7 mm in the former camera and 5 mm in the latter one. The total time required to perform the SPECT (12 minutes) and measure the parameters (5 minutes) was less than 25 minutes. In patients with internal carotid artery territory occlusion, the residual CBF was evaluated. Of 16 axial sec tions, the one section most clearly demonstrating the ischemic J Cereb Blood Flow Metab, Vol. 19, No.1, 1999 region was selected. The regions of interest in the ischemic area in the cerebral hemisphere (a), the corresponding region on the contralateral side (b), and the whole cerebellar hemisphere on the ischemic side (c) were set, and the mean count was deter mined in each region of interest. Linearity adjustment was made by assuming the blood flow in the normal cerebellar hemisphere to be 55 mLlI00 g/min (Shinohara et aI., 1985) according to the method of Lassen and associates (1988) . The CBF was assessed semiquantitatively by calculating two pa rameters: (1) the ratio of ischemic regional activity (R) to cer ebellar activity (CE) (RICE ratio = alc), and (2) the asymmetry index (AI = 1 +[b -a]/[a + b]). The regions of interest were hand drawn in apparent whole ischemic areas based on quali tative inspection of the regional CBF maps. The contralateral, mirror image region of interest was drawn automatically. The regions of interest in cerebellum were hand drawn in whole hemisphere on the ischemic side to avoid influence by crossed cerebellar diaschisis. First, the residual CBF was evaluated in the whole ischemic region for each patient. Second, to evaluate injury thresholds, the regions of interest in patients who had apparent cortical infarction on the follow-up computed tomog raphy (CT) scans were retrospectively determined separately in the infarcted region and noninfarcted region.
Arterial digital subtraction angiography was performed by the Seldinger method using a 5-French catheter using a 6-French femoral sheath. The tip of a Tracker-18 catheter (Target Therapeutics, Fremont, CA, U.S.A.) was advanced into the thrombus or upstream from the site of occlusion over a 0.356cm (0.014-inch) Taper Dasher guide wire (Target Therapeu tics). Urokinase (240,000 U) was dissolved in 20 mL of physi ologic saline and was injected manually for about 10 minutes. The Tracker catheter was moved frequently through the oc cluded segment to disrupt thrombus mechanically. Angiogra phy was performed by injection of contrast material through the Tracker catheter immediately after each infusion. This was re peated until recanalization of the occluded vessel was con firmed. The maximum dose of urokinase was 960,000 U. The patients were managed initially by intravenous injection of hep arin (5000 U) and by administration of 10% glycerol (200 mL) and micromolecular dextran (500 mL) during the therapy. Ce rebral angiography also was performed on the day after throm bolysis in most patients because the sheath catheter in the femoral artery usually was kept until the next day. No reocclu sion were seen in second angiography. Ticlopidine (200 mg/d) administration was started the day after treatment when no intracranial hemorrhage or systemic bleeding tendency was ob served.
The patient's neurologic status was evaluated on admission, the following day, and 1 week and 1 month after treatment according to the NIH Stroke Scale (Brott et aI., 1989) , which expresses the severity of neurologic status numerically from 0 (normal) to 42. An NIH score of 42 points was applied to patients who had died within 1 month of treatment. The out come was evaluated 1 month after onset according to the fol lowing five-grade outcome scale: 1. Excellent: No neurologic deficits were observed, and the patient had returned fully to previous activities. 2. Good: Mild neurologic deficits remained, but the patient had returned partly to previous activities. 3. Fair: Rehabilitation was difficult, but no assistance was needed in activities of daily life. 4. Poor: Assistance was needed in activities of daily life. 5. Death.
Acute ischemic stroke was classified into cardioembolic in farction and atherothrombotic infarction according to the guidelines of the Cerebral Embolism Task Force (1986) based on the onset pattern, angiographic findings, and results of car diovascular examinations such as EEG, echocardiography, and Holter electrocardiography.
For statistical analysis, the values were expressed as the mean ± SD, and differences among the three groups were ex amined by Scheff6' s F test.
RESULTS

Patient classification and outcome
Based on the follow-up CT, the patients were classi fied into three groups: A, 9 patients with no evidence of infarction, small subcortical infarctions, or spotty basal ganglial infarctions (Fig. 1) ; B, 14 patients with medium sized or large cortical infarctions (Fig. 2) ; and C, 7 pa tients with hemorrhagic transformation (Fig. 3) .
Clinical characteristics, treatment protocol, SPECT findings, and outcomes are summarized in Table 1 . Neu rologic outcome judged by the NIH score and clinical outcome judged by our five-grade outcome scale were significantly different among all three patients groups (P < 0.01). However, the duration of ischemia, disease type, sex, site of occlusion, and urokinase dose were not sig nificantly different among these three patients groups. Duration of ischemia (less than 5 hours) became signifi cant only in patients with severe ischemia (RICE ratio < 0.55). SPECT findings can differentiate the hemorrhagic group from both the reversible ischemia and infarction groups, but the difference between the reversible isch emia and infarction groups for the ischemic duration be tween 2 and 12 hours was not statistically significant. When patients are separated into two subgroups using the 5-hour duration of ischemia as the cutoff, SPECT findings can readily differentiate all three groups. Hem orrhagic transformation detected on CT scan immedi ately after treatment or on the following day occurred in seven patients. Neurologic deterioration was observed in the following five patients: two with massive parenchy mal hematomas, two with hematomas and extensive brain edema, and one with a medium hematoma in the basal ganglia. Hemorrhagic transformation significantly depended on residual CBF, age, and pretreatment NIH scores, even in patients with early and successful recana lization.
Ischemic lesion classification and cerebral blood flow thresholds for ischemic injury
By comparing the ischemic lesions judged by pretreat ment SPECT with noninfarcted, infarcted, and hemor rhagic regions judged by follow-up CT, 42 lesions (22 noninfarcted, 13 infarcted, and 7 hemorrhagic lesions) were identified in the 30 patients evaluated (Figs. 4 and 5) .
The average RICE ratios in the noninfarcted, infarcted, and hemorrhagic lesions were 0.62 ± 0.15, 0.41 ± 0.06, and 0.23 ± 0.08, respectively (Fig. 4) . The average AI values in the noninfarcted, infarcted, and hemorrhagic regions were 1.20 ± 0.12, 1.38 ± 0.13, and 1.60 ± 0.07, respectively. There was a significant difference in RICE ratio and AI between each region (P < 0.01). In all seven patients with hemorrhagic transformation, the RICE ratio and AI were less than 0.35 and more than 1.5, respec tively.
Within 5 hours after onset of symptoms, ischemic out come (reversible ischemia, infarction, and hemorrhage) appeared to depend on both pretreatment CBF and the duration of ischemia. After 5 hours from onset of symp toms, the ischemic outcome was influenced by only pre treatment CBF. Furthermore, the thresholds for the de velopment of infarction or hemorrhage were likely to be about 0.55 and about 0.35 of RICE ratio, respectively ( Fig. 5) .
These thresholds provide important information that can be potentially useful in the management of acute stroke patients with intra-arterial thrombolysis: (1) isch emic tissue with a flow index greater than 0.55 still may be salvageable, even when treatment is initiated 6 hours after onset of symptoms; (2) ischemic tissue with a flow index greater than 0.35 still may be salvageable with early treatment (less than 5 hours); and (3) ischemic tissue with a flow index below 0.35 may be at risk for hemorrhage, even when treatment is started within the critical time window.
DISCUSSION
Human and animal studies (Jones et a!., 1981; indicate that each minute of ischemia is harmful, and the sooner the treatment of ischemic stroke is begun, the better are the chances to minimize the isch emic damage. Emergency treatment has been focused on the first 6 hours after the onset of ischemic stroke symp toms. It is generally believed that the 6-hour period pro vides a therapeutic window of opportunity during which medical intervention can be initiated to limit brain dam age. Within this therapeutic window, it is presumed that most ischemic tissue remains viable and, theoretically, can be revived. The purpose in choosing a therapeutic window for early intervention has two distinctive goals:
(1) to improve the ischemic outcome by rescuing the reversible ischemic tissue, and (2) to avoid hemorrhagic complications caused by reperfusing irreversibly dam aged ischemic tissue. Improving the ischemic outcome by reducing the reperfusion injury can achieve a better neurologic outcome.
In recent studies using either intravenous or intra arterial thrombolytic therapy, not all of the patients had excellent ischemic outcomes, with significant hemor rhagic complications occurring even in those treated NS, not significant; ICA, internal cerebral artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; SPECT, single-photon emission-computed tomography; RICE ratio of ischemic regional activity (R) to cerebel lar activity (CE); AI, asymmetry index.
* Scheffe's F test.
t Measured in whole region of decreasing uptake of pretreatment SPECT. :j: Significant difference in groups either less than or more than 5-h duration of ischemia. § National Institutes of Health Stroke Scale score. .� within the therapeutic window. Analysis of the data from 261 patients in nine studies (del Zappa et aI., 1988; Mori et aI., 1988; Hacke et aI., 1988; Theron et aI., 1989; Ezura and Kagawa, 1992; Zeumer et aI., 1993; Ueda et aI., 1994; Jansen et aI., 1995; Sasaki et aI., 1995) using intra-arterial thrombolytic therapy with 59% recanaliza tion rate ranging from within 6 to within 24 hours after the onset of symptoms shows that neurologic improve ment was achieved in only 42% of patients, but hemor rhage occurred in 21 %. Interestingly, patients with ear lier treatment (less than 6 hours) did not always have a better neurologic outcome and less hemorrhagic compli cations compared with those with late treatment (less than 24 hours). The inconsistent results among these studies were expected because many potential problems existed in their design and performance. Therefore, there is an urgent need to design a clinical trial with strict criteria and standardized protocols to compensate for variables that influence outcome (Ferguson and Fergu son, 1994; del Zoppo et aI., 1994; Adams et aI., 1996) . Many issues were raised about the way previous studies were designed, including patient selection, classification of ischemic injury, vascular territories, drugs involved T. UEDA ET AL. and their dosages, and duration and route of administra tion of thrombolytic agents. Our preliminary data from a limited number of pa tients indicate that some of these issues may not always appear to have as much influence on neurologic outcome as we thought in patients with intra-arterial thrombolytic therapy (Table 1) . These issues include the duration of ischemia, classification of ischemic injury, size of isch emia, urokinase dose, disease type, and site of occlusion. However, our data suggest that pretreatment CBF influ ences ischemic outcome, and pretreatment CBF, age, and pretreatment NIH score also affect hemorrhagic rate. Furthermore, duration of ischemia influences ischemic outcome only in those with low pretreatment CBF and does not influence the hemorrhagic rate. Yuh and associates (1995) advocate pretreatment evaluation of tissue viability and reversibility judged by magnetic resonance (MR) perfusion imaging for better patient selection to improve the efficacy of thrombolytic therapy. Pretreatment evaluation of tissue perfusion has not been a part of the routine protocol for emergency treatment of acute stroke in the past. Our study design therefore provides an opportunity to evaluate the efficacy of intra-arterial thrombolytic therapy in a more ideal or perhaps less complicated situation in that all of our pa tients had early and complete recanalization (eliminate the technical variation) and pretreatment SPECT (add information reflecting tissue reversibility).
It is well known that the reversibility of ischemic tis-sue depends on the severity and duration of ischemia. Experimental studies show that brain injury can be lim ited by restoring the CBF within several hours (Jones et aI., 1981) . The ischemic tissue with a low CBF (<10 mLl100 g/min) as the ischemic core rapidly underwent irreversible damage. The concept of an ischemic penum bra surrounding the ischemic core was defined originally as a region of blood flow below that needed to sustain electric activity but above that required to maintain cel lular ionic gradient, which may in time lead to irrevers ible cellular damage (Symon et aI., 1977; Astrup et aI., 1981; Hossmann et aI., 1982 and 1994) . The concept of the ischemic penumbra is indicative of potentially re versible ischemic tissues with early and appropriate therapeutic interventions (Fisher and Garcia, 1996) . The classic CBF ranges for the penumbra is known to be around 10 to 20 mLl100 g/min in animal studies (Jones et aI., 1981) . Tamura and colleagues (1980) indicated that the flow threshold for middle cerebral artery occlu sion in cats was 12 to 15 mLl100 g/min maintained for over 2 hours. Clinical positron emission tomography studies suggest that CBF in the penumbra ranges from 7 to 17 mLflOO g/min (Furlan et aI., 1996) . Heiss and coworkers (1997) report that flumazenil positron emis sion tomography can detect irreversibly damaged isch emic tissue in their experimental study and first clinical applications. Although CBF reflected by SPECT is not an absolute measurement, our data suggest that the pre treatment CBF of ischemic tissue plays the most impor tant role in the influence of ischemic outcome including hemorrhagic complication, and the parameters provided by pretreatment SPECT have value in assessing the re versibility of ischemic tissue. Although the therapeutic window in humans is gener ally believed to be the first 6 hours after the onset of symptoms, our data show a variation among different individuals. We believe that the therapeutic window for potentially salvageable ischemic tissue is likely depen dent on the degree of collateral flow and metabolic status (Yuh et aI., 1995) . For patients with higher pretreatment CBF, the therapeutic window may be much longer (up to 12 hours in our series) than for those with low pretreat ment CBF (less than 5 hours) ( Figs. 4 and 5 ). Furlan and colleagues (1996) report a therapeutic window of up to 16 hours, which is much longer than the popularly pro posed 3-to 6-hour window. Moreover, the therapeutic window in patients with occlusion of the posterior cir culation may be relatively longer than that in patients with occlusion of the anterior circulation (Hacke et aI., 1988) . Zeumer and associates (1993) suggest that intra arterial thrombolytic therapy for occlusion of the internal carotid artery or middle cerebral artery should be started within 5 hours. Our data are consistent with the data of Zeumer and others, suggesting that 5 hours rather than 6 hours is a preferable cutoff time for the therapeutic win-dow. However, our data also indicate that the 5-hour therapeutic window applies only to those with low pre treatment CBP judged by SPECT.
Hemorrhagic transformation is believed to be caused by reperfusing irreversibly damaged tissue. Hemorrhagic transformation after thrombolytic therapy can be classi fied into hemorrhagic infarction and parenchymal hema toma. Hemorrhagic infarction and parenchymal hema toma with extensive brain edema often aggravate the neurologic symptoms and adversely influence neurologic outcome (Overgaard et aI., 1990; Lyden and Zivin, 1993) . Although the incidence of spontaneous hemor rhagic transformation including asymptomatic hemor rhage was reported to be 15% to 43% (Toni et aI., 1996) , there is evidence that intravenous thrombolytic therapy increases the hemorrhagic transformation rate (Multicen tre Acute Stroke Trial-Italy (MAST-I) Group, 1995; The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, 1995; The Multicenter Acute Stroke Trial-Europe Study Group, 1996) . Delayed re canalization, particularly in intravenous recombinant tis sue plasminogen activator (rt-PA) infusion, increases the chance of reperfusing ischemic tissue that has ischemic duration beyond that individual's therapeutic window. Although the difference in overall hemorrhagic events (rt-PA 42.8%; placebo 36.8%) in the European Coopera tive Acute Stroke Study (Hacke et aI., 1995) was not significant between the two groups, the occurrence of large parenchymal hemorrhages was significantly more frequent in the rt-PA treatment group (19.8% versus 6.5%).
On the other hand, early recanalization, especially in intra-arterial rt -P A or urokinase infusion, can cause a sudden rise in intravascular pressure, and parenchymal hematomas can develop if ischemic tissue has been irre versibly damaged, particularly in individuals who have short therapeutic windows. In intra-arterial infusion stud ies, hemorrhagic transformation was reported in a mean of 21 % of patients within the reported range of sponta neous hemorrhage rate. Recently, in a randomized, con trolled, double-blind trial of intra-arterial recombinant prourokinase, there was no difference between the fre quency of brain hemorrhage with clinical deterioration when comparing the recombinant prourokinase (15 % ) and placebo (14%) groups (del Zoppo et aI., 1998) .
In the current study, hemorrhagic transformation oc curred in 23%, and parenchymal hematoma was ob served in 17%. Most hemorrhagic transformation oc curred in patients within the 6-hour therapeutic window (71 % between 3 and 5 hours), indicating that early in tervention may not always be helpful and other factors also must be considered (Pigs. 4 and 5). Moreover, the incidence of hemorrhagic transformation in patients with thrombotic middle cerebral artery occlusion was reported to be less than that in patients with embolic middle ce-rebral artery occlusion because the mean residual CBP was significantly higher in the former than in the latter (Ueda et aI., 1997) . We observed that patients with hem orrhagic transformation were significantly older, with a much lower residual CBP (RICE ratio < 0.35) and higher pretreatment NIH score than those without hemorrhagic transformation.
Other factors also may influence hemorrhagic trans formation. Levy and associates (1994) report that factors significantly related to the development of an intracere bral hematoma were rt-PA dose and diastolic hyperten sion. Ueda and others (1995) suggest that although intra arterial thrombolysis should not theoretically exert a greater influence on systemic coagulation and fibrinolyt ic factors than intravenous thrombolysis, the administra tion of high-dose rt -P A induced greater changes in those factors. Alexandrov and associates (1997a) indicate that a high risk of cardioembolism, M1 occlusion, and ab sence of collateral flow helped to identify patients at risk for spontaneous hemorrhagic transformation.
Computed tomography has been a valuable pretreat ment imaging tool in the evaluation of patients with acute stroke for possible thrombolytic therapy. The early signs of ischemia on CT scans are associated with severe ischemic stroke and a poor clinical outcome (von Kum mer et aI., 1994; Yokogami et aI., 1996; Tarr et aI., 1996) . Based on our results, it may be reasonable to assume that early, abnormal CT findings are indicative of a markedly low CBF. However, normal CT findings do occur in patients with a poor outcome, suggesting that the severity of hypoperfusion may not always be appre ciated by early CT scans and perfusion studies may be helpful in such situations.
The CBP study using HMPAO-SPECT has advan tages in that it is readily available and can be performed quickly in emergency cases (Herderschee et aI., 1991) . In addition, the value of this technique in the management of stroke has been established in the past (Hanson et aI., 1993; Baird et aI., 1994) . Shimosegawa and associates (1994) indicate that the lesion-to-contralateral radioac tivity ratio for infarction threshold was 0.48 ± 0.14 in patients without thrombolytic therapy who underwent imaging within 6 hours after onset, findings which are similar to ours. Sasaki and colleagues (1996) demon strated that reperfusion in only nine patients within 7'/4 hours from onset significantly reduced the development of infarction in a RICE ratio between 0.55 and 0.75. Ezura and coworkers (1996) indicate that moderate isch emia with residual relative regional CBP of between 0.35 and 0.70 might be suitable for intra-arterial thrombolysis by evaluation of only seven patients. Our data show that the pretreatment CBP judged by SPECT in 42 lesions of 30 patients with complete recanalization is significantly different among reversible ischemia, infarction, and hemorrhage (Pigs. 4 and 5). The development of infarc-tion and hemorrhagic transformation depend mainly on pretreatment CBF, and most patients with hemorrhagic transformation have had severe ischemic injury and ir reversible damage within the so-called 6-hour therapeu tic window. In this study, within 5 hours after onset of symptoms, the development of infarction or hemorrhage appeared to depend on both the residual CBF and on the duration of ischemia, whereas after 5 hours from onset, the thresholds for the development of infarction or hem orrhage were likely to be about 0.55 and about 0.35 of RICE ratio, respectively.
Perhaps most importantly, our data show that the re sidual CBF by initial SPECT correlated with the neuro logic outcome, supporting the notion that SPECT pro vides important information for determining whether thrombolytic therapy is worthwhile by predicting isch emic outcome, including associated hemorrhagic risk and neurologic outcome, at any given time point within or beyond the so-called 6-hour therapeutic window (Ueda et aI., 1996) . Patients having a high CBF (RICE ratio> 0.55) should be treated, regardless of how long it has been beyond the 6-hour therapeutic window after onset (our data suggest that it can be up to 12 hours). On the other hand, the outcome of patients with low CBF could be improved only if they were treated within 5 hours.
With recent advances in fast imaging techniques, in cluding echo-planar imaging, MR imaging may be an other potentially useful means to assess tissue viability and reversibility before thrombolytic therapy. Diffusion MR imaging is reported to be useful clinically in the diagnosis of hyperacute ischemic stroke as early as 30 minutes after onset without treatment (Warach et aI., 1995) . Kohno and colleagues (1995) report that the CBF threshold in detecting abnormal signal intensity on dif fusion MR imaging was 41 mL/IOO g/min 2 hours after middle cerebral artery occlusion in rats, which is sub stantially higher than the infarction threshold. This sug gests that diffusion imaging is a sensitive means of de tecting of ischemia. However, whether the diffusion ab normality can be used to evaluate tissue reversibility at any given time point remains to be determined. Perfusion MR imaging is reported to provide information related to microcirculation of the brain parenchyma. Perfusion MR imaging is based mainly on hemodynamic phenomena (kinetic) rather than a biological process; as in spectros copy and diffusion imaging, it can readily detect flow abnormalities and is ideal for evaluating hyperacute isch emic stroke (Maeda et aI., 1997) . Information related to tissue perfusion status can be available within 25 minutes in our institution using echo-planar imaging technique. More semiquantitative data similar to those acquired by SPECT techniques in our study are needed to judge the capability of perfusion MR imaging in assessing tissue reversibility before thrombolytic therapy (Yuh et aI., J Cereb Blood Flow Metab, Vol. 19. No. J, 1999 1995). Similarly, stable xenon-CT (Touho and Karasawa, 1996; Firlik et aI., 1997) and dynamic CT are other meth ods that also may have the potential to provide informa tion related to the reversibility of ischemic tissue for the treatment of acute stroke.
In conclusion, based on our limited data, outcomes of acute cerebral ischemia with early and complete recana lization using intra-arterial thrombolytic therapy are sig nificantly different and are influenced markedly by pre treatment CBF assessed by SPECT. The CBF thresholds evaluated by SPECT provide important information that can be potentially useful in the management of acute stroke patients with intra-arterial thrombolysis: (1) isch emic tissue with a flow index greater than 0.55 still may be salvageable even with treatment initiated 6 hours after onset of symptoms; (2) ischemic tissue with a flow index greater than 0.35 still may be salvageable with early treatment (less than 5 hours); and (3) ischemic tissue with a flow index below 0.35 may be at risk for hemor rhage, even when treatment is started within the critical time window. Our study suggests that SPECT is a non invasive, readily available, and convenient means that can provide useful parameters to predict patient outcome before treatment. When combined with clinical informa tion and, in some patients, the duration of ischemia, it may be potentially useful to improve patient selection for thrombolytic therapy and therefore its efficacy.
